Skip to main content
. 2020 Oct 21;11(5):1341–1354. doi: 10.1016/j.apsb.2020.10.015

Figure 3.

Figure 3

In vitro tumor targeting and synergistic anti-tumor effect of DOX and LAP combo. (A) Uptake of various IR780-loaded NPs in 231Br cells. Data are presented as mean ± SD (n = 4). (B) Uptake of IR780-loaded NPs in 231Br cells, which were un-pretreated or pre-incubated in PBS/MCM (1:9, v/v) for 24 h. Data are presented as mean ± SD (n = 4). (C) Viability of 231Br cells after treated with empty NPs-K-s-A for 48 h. Data are presented as mean ± SD (n = 6). (D) Dose effect curves on 231Br cells exposed to DOX-loaded NPs-K-s-A, LAP-loaded NPs-K-s-A, and COMBO NPs at different DOX/LAP weight ratios for 48 h. The fraction of 231Br cells affected (Fa) was shown. (E) The Chou–Talalay analysis of the dose effect curve in (D). Combination index (CI) values for different DOX/LAP weight ratios are provided for all Fa levels. The data were determined by the Chou–Talalay analysis model using Fa levels for actual doses. (F) IC50 values of different COMBO formulations (DOX/LAP = 1:1.5) on 231Br cells after incubation for 48 h. Data are presented as mean ± SD (n = 3). ∗∗P < 0.01, ∗∗∗P < 0.001.